药物相关性颌骨坏死研究进展

doi:10.12337/zgkqzzxzz.2024.10.016

摘要/Abstract

摘要： 在应用抗骨吸收药物,如双膦酸盐和地舒单抗,以及血管生成抑制剂的患者群体中,进行相关口腔疾病的治疗可能会诱发药物相关性颌骨坏死（medication-related osteonecrosis of the jaw,MRONJ）。然而,MRONJ的确切机制尚不清楚,尽管大量研究已经创建了临床治疗数据库,但明确的治疗策略尚未制定。本研究通过文献回顾,对MRONJ的定义、病因、分期、危险因素、治疗和预防进行了相关讨论,为口腔临床工作提供参考。

Abstract: Medication-related osteonecrosis of the jaw (MRONJ) may be induced during the treatment of oral diseases in patients receiving anti-resorptive drugs such as bisphosphonates and denosumab, as well as angiogenesis inhibitors. However, the exact mechanism of MRONJ remains unclear, and although numerous studies have established clinical treatment databases, definitive treatment strategies have yet to be developed. Through a review of the literature, this study discusses the definition, etiology, staging, risk factors, treatment and prevention of MRONJ, providing a reference for clinical practice in oral healthcare.

Key words: Bisphosphonate-related osteonecrosis of the jaw, Medication-related osteonecrosis of the jaw, Bisphosphonates, Denosumab

高婷婷,鲍永接,吕晓燕,等. 药物相关性颌骨坏死研究进展[J]. 中国口腔种植学杂志, 2024, 29(5): 492-497. DOI: 10.12337/zgkqzzxzz.2024.10.016

Gao Tingting, Bao Yongjie, Lv Xiaoyan, Chen Xian, Liu Yang, Xu Yilei, Lu Huanyou. Research progress on medication-related osteonecrosis of the jaw[J].Chinese Journal of Oral Implantology, 2024, 29(5): 492-497.DOI: 10.12337/zgkqzzxzz.2024.10.016.

参考文献

[1] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003,61(9):1115-1117. DOI: 10.1016/s0278-2391(03)00720-1.
[2] Drake MT, Clarke BL, Khosla S.Bisphosphonates: mechanism of action and role in clinical practice[J]. Mayo Clin Proc, 2008,83(9):1032-1045. DOI: 10.4065/83.9.1032.
[3] Rogers MJ, Mönkkönen J, Munoz MA.Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton[J]. Bone, 2020,139:115493. DOI: 10.1016/j.bone.2020.115493.
[4] Aghaloo TL, Felsenfeld AL, Tetradis S.Osteonecrosis of the jaw in a patient on Denosumab[J]. J Oral Maxillofac Surg, 2010,68(5):959-963. DOI: 10.1016/j.joms.2009.10.010.
[5] Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis[J]. N Engl J Med, 2009,361(8): 756-765. DOI: 10.1056/NEJMoa0809493.
[6] Xu J, Li H, Qu Y, et al.Denosumab might prevent periprosthetic bone loss after total hip and knee arthroplasties: a review[J]. Arthroplasty, 2021,3(1):13. DOI: 10.1186/s42836-021-00068-6.
[7] Storm NE, Chang W, Lin TC, et al.A novel case study of the use of real-world evidence to support the registration of an osteoporosis product in China[J]. Ther Innov Regul Sci, 2022,56(1):137-144. DOI: 10.1007/s43441-021-00342-4.
[8] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update[J]. J Oral Maxillofac Surg, 2014,72(10):1938-1956. DOI: 10.1016/j.joms.2014.04.031.
[9] Silveira FM, Etges A, Correa MB, et al.Microscopic evaluation of the effect of oral microbiota on the development of bisphosphonate-related osteonecrosis of the jaws in rats[J]. J Oral Maxillofac Res, 2016,7(4):e3. DOI: 10.5037/jomr.2016.7403.
[10] Colella G, Campisi G, Fusco V.American Association of Oral and Maxillofacial Surgeons' position paper: bisphosphonate-related osteonecrosis of the jaws—2009 update: the need to refine the BRONJ definition[J]. J Oral Maxillofac Surg, 2009,67(12):2698-2699. DOI: 10.1016/j.joms.2009.07.097.
[11] Campisi G, Mauceri R, Bertoldo F, et al.Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian Consensus Update 2020[J]. Int J Environ Res Public Health, 2020,17(16):5998. DOI: 10.3390/ijerph17165998.
[12] Ruggiero SL, Dodson TB, Aghaloo T, et al.American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws—2022 update[J]. J Oral Maxillofac Surg, 2022,80(5):920-943. DOI: 10.1016/j.joms.2022.02.008.
[13] Aghaloo TL, Kang B, Sung EC, et al.Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat[J]. J Bone Miner Res, 2011,26(8):1871-1882. DOI: 10.1002/jbmr.379.
[14] Huja SS, Fernandez SA, Hill KJ, et al.Remodeling dynamics in the alveolar process in skeletally mature dogs[J]. Anat Rec A Discov Mol Cell Evol Biol, 2006,288(12):1243-1249. DOI: 10.1002/ar.a.20396.
[15] Yeung MK.Molecular and genetic analyses of actinomyces spp[J]. Crit Rev Oral Biol Med, 1999,10(2):120-138. DOI: 10.1177/10454411990100020101.
[16] Kang B, Cheong S, Chaichanasakul T, et al.Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice[J]. J Bone Miner Res, 2013,28(7):1631-1640. DOI: 10.1002/jbmr.1894.
[17] Landesberg R, Woo V, Cremers S, et al.Potential pathophysiological mechanisms in osteonecrosis of the jaw[J]. Ann N Y Acad Sci, 2011,1218:62-79. DOI: 10.1111/j.1749-6632.2010.05835.x.
[18] Vallina C, Ramírez L, Torres J, et al.Osteonecrosis of the jaws produced by sunitinib: a systematic review[J]. Med Oral Patol Oral Cir Bucal, 2019,24(3):e326-e338. DOI: 10.4317/medoral.22858.
[19] 潘剑, 刘济远. 药物相关性颌骨坏死的发病机制及其防治[J].华西口腔医学杂志, 2021,39(3):245-254. DOI: 10.7518/hxkq.2021.03.001.
[20] Tseng HC, Kanayama K, Kaur K, et al.Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation[J]. Oncotarget, 2015,6(24):20002-20025. DOI: 10.18632/oncotarget.4755.
[21] 刘忠龙, 姜钧健, 李晓光, 等. 一种新的药物性颌骨坏死临床分期及治疗策略[J].中国口腔颌面外科杂志, 2020,18(6):501-507. DOI: 10.19438/j.cjoms.2020.06.006.
[22] Barrette LX, Suresh N, Salmon MK, et al.Assessment of clinical guidelines for medication-related osteonecrosis of the jaw: current status and future directions[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2022,134(6):717-724. DOI: 10.1016/j.oooo.2022.06.014.
[23] Kuroshima S, Al-Omari FA, Sasaki M, et al.Medication-related osteonecrosis of the jaw: a literature review and update[J]. Genesis, 2022,60(8-9):e23500. DOI: 10.1002/dvg.23500.
[24] Saad F, Brown JE, Van Poznak C, et al.Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases[J]. Ann Oncol, 2012,23(5):1341-1347. DOI: 10.1093/annonc/mdr435.
[25] Wilde F, Heufelder M, Winter K, et al.The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011,111(2):153-163. DOI: 10.1016/j.tripleo.2010.04.015.
[26] Fliefel R, Tröltzsch M, Kühnisch J, et al.Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review[J]. Int J Oral Maxillofac Surg, 2015,44(5):568-585. DOI: 10.1016/j.ijom.2015.01.026.
[27] McLeod NM, Patel V, Kusanale A, et al. Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw[J]. Br J Oral Maxillofac Surg, 2011,49(5):335-342. DOI: 10.1016/j.bjoms.2010.08.005.
[28] de Souza Tolentino E, de Castro TF, Michellon FC, et al. Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: systematic review[J]. Head Neck, 2019,41(12):4209-4228. DOI: 10.1002/hed.25944.
[29] Bashutski JD, Eber RM, Kinney JS, et al.Teriparatide and osseous regeneration in the oral cavity[J]. N Engl J Med, 2010,363(25):2396-2405. DOI: 10.1056/NEJMoa1005361.
[30] 楚立园, 姜苗, 董青, 等. 仙方活命饮加减治疗唑来膦酸相关性下颌骨坏死验案一例[J].环球中医药, 2022,15(4):677-680. DOI: 10.3969/j.issn.1674-1749. 2022. 04.029.
[31] 朱鑫美. 低能量激光疗法治疗药物相关性颌骨坏死的研究进展[J].现代医药卫生, 2022,38(8):1326-1330. DOI: 10.3969/j.issn.1009-5519.2022.08.014.
[32] 曾叶渐, 王军, 邹海啸. 富血小板纤维蛋白在药物相关性颌骨坏死预防和治疗中的研究进展[J].中国实用口腔科杂志, 2023,16(6):752-756. DOI: 10.19538/j.kq.2023. 06.019.
[33] Carlson ER.Management of antiresorptive osteonecrosis of the jaws with primary surgical resection[J]. J Oral Maxillofac Surg, 2014,72(4):655-657. DOI: 10.1016/j.joms.2013.12.007.
[34] Watters AL, Hansen HJ, Williams T, et al.Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013,115(2):192-200. DOI: 10.1016/j.oooo.2012.05.017.
[35] Ristow O, Rückschloß T, Müller M, et al.Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study[J]. J Craniomaxillofac Surg, 2019,47(3):491-499. DOI: 10.1016/j.jcms.2018.12.014.
[36] Curtin BM, Fehring TK.Bisphosphonate fractures as a cause of painful total hip arthroplasty[J]. Orthopedics, 2011,34(12):e939-e944. DOI: 10.3928/01477447-20111021-36.
[37] Fiorillo L, Cicciù M, Tözüm TF, et al.Impact of bisphosphonate drugs on dental implant healing and peri-implant hard and soft tissues: a systematic review[J]. BMC Oral Health, 2022,22(1):291. DOI: 10.1186/s12903-022-02330-y.
[38] Chadha GK, Ahmadieh A, Kumar S, et al.Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: a systematic review[J]. J Oral Implantol, 2013,39(4):510-520. DOI: 10.1563/AAID-JOI-D-11-00234.
[39] Vandone AM, Donadio M, Mozzati M, et al.Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience[J]. Ann Oncol, 2012,23(1):193-200. DOI: 10.1093/annonc/mdr039.
[40] Patel V, McLeod NM, Rogers SN, et al. Bisphosphonate osteonecrosis of the jaw--a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention[J]. Br J Oral Maxillofac Surg, 2011,49(4):251-257. DOI: 10.1016/j.bjoms.2010.05.007.
[41] Ripamonti CI, Maniezzo M, Campa T, et al.Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan[J]. Ann Oncol, 2009,20(1):137-145. DOI: 10.1093/annonc/mdn526.
[42] Wick A, Bankosegger P, Otto S, et al.Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab[J]. Clin Oral Investig, 2022,26(3):2839-2852. DOI: 10.1007/s00784-021-04261-4.
[43] Taguchi A, Shiraki M, Sugimoto T, et al.Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw[J]. Curr Med Res Opin, 2016,32(7):1261-1268. DOI: 10.1185/03007995.2016.1170005.
[44] Taguchi A, Hagino H, Inoue D, et al.Cooperation between physicians and dentists for osteonecrosis of the jaw: a 2022 Japanese survey[J]. J Bone Miner Metab, 2023,41(6):829-837. DOI: 10.1007/s00774-023-01458-3.
[45] Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al.Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians[J]. Ann Intern Med, 2023,176(2):224-238. DOI: 10.7326/M22-1034.
[46] Aljohani S.Awareness, perceptions and attitudes toward medication-related osteonecrosis of the jaw among physicians who treat osteoporosis[J]. Saudi Pharm J, 2023,31(9):101707. DOI: 10.1016/j.jsps.2023.101707.